Americans were hoping the FDA would be reformed. But it looks like Trump still has some work to do.
As the FDA pushes a dangerous drug through safety protocols in a move that is completely terrifying.
In a stunning slap in the face to pro-life Americans, the FDA has just greenlit a new generic version of the abortion pill mifepristone, right under the nose of Health Secretary Robert F. Kennedy Jr., who had vowed to scrutinize its safety. This move has ignited fury across conservative circles
weeks, got the thumbs-up from the FDA on Tuesday, mere hours before the government shutdown kicked in. The agency’s nod came via an “abbreviated new drug application.”
“We have completed the review … and have concluded that adequate information has been presented to demonstrate that the drug meets the requirements for approval,” said the letter from the FDA to Evita Solutions.
Kennedy tried to dodge the heat by claiming the FDA’s hands were tied by federal rules. “[FDA] only approved a second generic mifepristone tablet because federal law requires approval when an application proves the generic is identical to the brand-name drug,” he said in a post on X.
As head of the Department of Health and Human Services, which oversees the FDA, Kennedy had earlier assured lawmakers he’d dig deep into mifepristone’s risks. This came after a d*mning study highlighted dangers for women using the pill.
The research from the Ethics & Public Policy Center revealed that nearly 11% of women who took mifepristone faced a “serious adverse event.” Kennedy himself called it alarming during his congressional testimony.
“I have asked Marty Makary, who is the director at FDA, to do a complete review and report back,” Kennedy said during his testimony that was given to the Senate Health, Labor, Education and Pensions Committee earlier this year.
Just days before the approval, Kennedy and FDA Commissioner Marty Makary penned a letter to Republican attorneys general, insisting a review was in progress. “HHS — through the FDA — is conducting its own review of the evidence, including real-world outcomes and evidence, relating to the safety and efficacy of the drug,” they wrote.
“This Administration will ensure that women’s health is properly protected by thoroughly investigating the circumstances under which mifepristone can be safely dispensed.”
Senator Josh Hawley from Missouri, a no-nonsense fighter for conservative causes, was rightfully upset. He slammed the FDA’s decision as downright “shocking,” especially after their pledges for a full safety overhaul.
“FDA had promised to do a top-to-bottom safety review of the chemical abortion drug, but instead they’ve just greenlighted new versions of it for distribution,” the senator said in a post on X. “I have lost confidence in the leadership at FDA.”
Former Vice President Mike Pence, now steering the ship at Advancing American Freedom, went even further. He demanded Kennedy step down, seeing this as a direct stab in the back to the pro-life warriors who backed Trump.
“The Trump Administration’s approval of a generic chemical abortion drug is a complete betrayal of the pro-life movement that elected President Trump,” Pence posted on X.
“Earlier this year, I opposed RFK’s nomination because he was unfit for the role and particularly over the concern that he would expand access to abortion, as he has done today,” he added.
Pence didn’t stop there—he urged Trump to flip this decision on its head. “RFK must resign and give President Trump the opportunity to appoint a new Secretary of HHS who will protect the sanctity of life.”
Kennedy’s history of soft-on-abortion stances raised red flags from the start when Trump picked him for HHS. Republicans in Congress grilled him hard, and for good reason.
In the end, this generic pill approval isn’t just about one drug; it’s a test of whether this administration will stand firm against the abortion industry’s grip.
Stay tuned to The Federalist Wire.
